New vaccine approaches to create antibodies against HIV
Official title: Novel vaccine strategies to induce V2 apex-directed broad neutralizing antibodies
Funded at Applied Biomedical Science Institute · NIH-10641021 · Data updated 2026-11-12
This study is working on a new vaccine to help your body make strong defenses against HIV by learning how to boost certain antibodies, and it's being tested in specially modified mice to find the best way to protect people from the virus.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Applied Biomedical Science Institute NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project start | July 4, 2019 |
| Project end | June 30, 2025 |
| Funding year | 2023 |
| Award (this year) | $945,717 |
| NIH project number | 5R01AI141338-05 |
| Project ID | NIH-10641021 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at high risk for HIV infection or those living with HIV who are interested in new preventive strategies.
✕Less likely to help
Patients who are not at risk for HIV or those who are already receiving effective treatment for HIV may not benefit from this research.
What this research studies
This research focuses on developing a vaccine that can effectively induce broadly neutralizing antibodies (bnAbs) to protect against HIV-1 infection. The team is using genetically modified mice to study how these antibodies mature and identifying specific features that can be targeted for vaccine development. By understanding the challenges in eliciting these antibodies, the researchers aim to create a vaccine regimen that can successfully generate a strong immune response against HIV. This work is crucial as current vaccines have not been able to produce the desired immune response.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking vaccine that provides protection against HIV-1, significantly impacting public health.
How similar studies have gone: While there have been various attempts to develop HIV vaccines, this approach using genetically modified models is relatively novel and has not been extensively tested in human trials.
Where this research is happening
-
Applied Biomedical Science Institute
San Diego, United States Active
Researchers
- Principal investigator: Verkoczy, Laurent Karl — Applied Biomedical Science Institute
- Study coordinator: Verkoczy, Laurent Karl
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.